ME03430B - Jedinjenja amida kao agonisti 5-ht4 receptora - Google Patents
Jedinjenja amida kao agonisti 5-ht4 receptoraInfo
- Publication number
- ME03430B ME03430B MEP-2019-190A MEP2019190A ME03430B ME 03430 B ME03430 B ME 03430B ME P2019190 A MEP2019190 A ME P2019190A ME 03430 B ME03430 B ME 03430B
- Authority
- ME
- Montenegro
- Prior art keywords
- receptoragonists
- amide compounds
- amide
- compounds
- Prior art date
Links
- -1 AMIDE COMPOUNDS Chemical class 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN709CH2015 | 2015-02-13 | ||
| EP16711355.4A EP3265459B1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
| PCT/IN2016/000008 WO2016128990A1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03430B true ME03430B (me) | 2020-01-20 |
Family
ID=55588327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-190A ME03430B (me) | 2015-02-13 | 2016-01-07 | Jedinjenja amida kao agonisti 5-ht4 receptora |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9957257B2 (me) |
| EP (1) | EP3265459B1 (me) |
| JP (1) | JP6487564B2 (me) |
| KR (1) | KR101966576B1 (me) |
| CN (1) | CN107406434B (me) |
| AU (1) | AU2016217461B2 (me) |
| BR (1) | BR112017017275A2 (me) |
| CA (1) | CA2975973C (me) |
| CY (1) | CY1121898T1 (me) |
| DK (1) | DK3265459T3 (me) |
| EA (1) | EA034618B1 (me) |
| ES (1) | ES2734734T3 (me) |
| HR (1) | HRP20191179T1 (me) |
| HU (1) | HUE045667T2 (me) |
| IL (1) | IL253848B (me) |
| LT (1) | LT3265459T (me) |
| MA (1) | MA41633B1 (me) |
| MD (1) | MD3265459T2 (me) |
| ME (1) | ME03430B (me) |
| MX (1) | MX368214B (me) |
| NZ (1) | NZ734400A (me) |
| PL (1) | PL3265459T3 (me) |
| PT (1) | PT3265459T (me) |
| RS (1) | RS59066B1 (me) |
| SG (1) | SG11201706501VA (me) |
| SI (1) | SI3265459T1 (me) |
| SM (1) | SMT201900398T1 (me) |
| TR (1) | TR201909997T4 (me) |
| WO (1) | WO2016128990A1 (me) |
| ZA (1) | ZA201705292B (me) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110818661B (zh) * | 2019-12-02 | 2021-08-06 | 上海再启生物技术有限公司 | 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004026095D1 (de) | 2003-11-24 | 2010-04-29 | Pfizer | Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| CA2598516C (en) | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Benzisoxazole derivatives |
| CA2615611C (en) | 2005-07-22 | 2011-09-27 | Pfizer Inc. | Indazole derivatives |
| WO2007048643A1 (en) * | 2005-10-28 | 2007-05-03 | Glaxo Group Limited | Novel compound |
| GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| GB0603550D0 (en) * | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
| JP6023926B2 (ja) * | 2010-02-12 | 2016-11-09 | 株式会社ＡｓｋＡｔ | 認知症治療のための５−ｈｔ４受容体アゴニスト |
| CA2788656A1 (en) | 2010-02-16 | 2011-08-25 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
| PT2758394E (pt) * | 2011-09-19 | 2015-04-22 | Suven Life Sciences Ltd | Compostos heteroarilo como ligandos de recetores 5-ht4 |
| CN105164119B (zh) * | 2013-03-20 | 2017-12-08 | 苏文生命科学有限公司 | 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 |
| MX368017B (es) * | 2013-12-16 | 2019-09-13 | Suven Life Sciences Ltd | Compuestos de indazol como agonistas del receptor de 5-ht4. |
-
2016
- 2016-01-07 SG SG11201706501VA patent/SG11201706501VA/en unknown
- 2016-01-07 SM SM20190398T patent/SMT201900398T1/it unknown
- 2016-01-07 MA MA41633A patent/MA41633B1/fr unknown
- 2016-01-07 MD MDE20180052T patent/MD3265459T2/ro not_active IP Right Cessation
- 2016-01-07 DK DK16711355.4T patent/DK3265459T3/da active
- 2016-01-07 PL PL16711355T patent/PL3265459T3/pl unknown
- 2016-01-07 HR HRP20191179TT patent/HRP20191179T1/hr unknown
- 2016-01-07 EA EA201791829A patent/EA034618B1/ru unknown
- 2016-01-07 MX MX2017010348A patent/MX368214B/es active IP Right Grant
- 2016-01-07 SI SI201630311T patent/SI3265459T1/sl unknown
- 2016-01-07 JP JP2017542107A patent/JP6487564B2/ja not_active Expired - Fee Related
- 2016-01-07 RS RS20190836A patent/RS59066B1/sr unknown
- 2016-01-07 NZ NZ734400A patent/NZ734400A/en not_active IP Right Cessation
- 2016-01-07 WO PCT/IN2016/000008 patent/WO2016128990A1/en not_active Ceased
- 2016-01-07 ES ES16711355T patent/ES2734734T3/es active Active
- 2016-01-07 ME MEP-2019-190A patent/ME03430B/me unknown
- 2016-01-07 KR KR1020177025584A patent/KR101966576B1/ko not_active Expired - Fee Related
- 2016-01-07 HU HUE16711355A patent/HUE045667T2/hu unknown
- 2016-01-07 TR TR2019/09997T patent/TR201909997T4/tr unknown
- 2016-01-07 PT PT16711355T patent/PT3265459T/pt unknown
- 2016-01-07 LT LTEP16711355.4T patent/LT3265459T/lt unknown
- 2016-01-07 AU AU2016217461A patent/AU2016217461B2/en not_active Ceased
- 2016-01-07 CN CN201680015614.4A patent/CN107406434B/zh not_active Expired - Fee Related
- 2016-01-07 BR BR112017017275A patent/BR112017017275A2/pt not_active IP Right Cessation
- 2016-01-07 EP EP16711355.4A patent/EP3265459B1/en active Active
- 2016-01-07 CA CA2975973A patent/CA2975973C/en not_active Expired - Fee Related
- 2016-01-07 US US15/549,663 patent/US9957257B2/en active Active
-
2017
- 2017-08-04 ZA ZA2017/05292A patent/ZA201705292B/en unknown
- 2017-08-06 IL IL253848A patent/IL253848B/en active IP Right Grant
-
2019
- 2019-07-10 CY CY20191100739T patent/CY1121898T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4226898C0 (de) | Aktuator-dämpfer-einheit | |
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| PT3157915T (pt) | Compostos de dihidroisoquinolinona substituídos | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| CL2016002129A1 (es) | Compuestos de azolina | |
| LT3197883T (lt) | Nauji junginiai | |
| PT3298027T (pt) | Compostos depsipéptidos antelmínticos | |
| DK3330593T3 (da) | Halo-lysenhed | |
| ME03430B (me) | Jedinjenja amida kao agonisti 5-ht4 receptora | |
| EP3334726A4 (en) | PINABULIN COMPOSITIONS | |
| LT3464336T (lt) | Junginiai | |
| LT3362444T (lt) | Junginiai | |
| CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
| EP3309163A4 (en) | SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE | |
| DK3597189T3 (da) | Krystallinske forbindelser | |
| LT3183242T (lt) | Pakeistieji bicikliniai junginiai | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| BR112018001062A2 (pt) | compostos inovadores | |
| EP3384016A4 (en) | MANIPULATED PHAGEMIDES | |
| HUE039805T2 (hu) | Új szulfonilaminobenzamid vegyületek | |
| EP3357916A4 (en) | benzamide | |
| DK3347403T3 (da) | Polyalkoxyfedtforbindelse | |
| DE102015206660A8 (de) | Plattenaufteilanlage | |
| EP3383846A4 (en) | Carbon monoxide releasing norbornenone compounds | |
| LT3331885T (lt) | Junginiai |